Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 4.5%

Pliant Therapeutics, Inc. (NASDAQ:PLRXGet Free Report) traded down 4.5% on Friday . The company traded as low as $12.71 and last traded at $12.80. 185,420 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 399,378 shares. The stock had previously closed at $13.40.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Citigroup lowered their price objective on shares of Pliant Therapeutics from $45.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Oppenheimer lifted their price target on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 7th. Royal Bank of Canada decreased their price objective on shares of Pliant Therapeutics from $54.00 to $45.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a research note on Tuesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of Pliant Therapeutics in a research note on Wednesday, May 15th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $45.38.

Check Out Our Latest Stock Analysis on Pliant Therapeutics

Pliant Therapeutics Price Performance

The company has a quick ratio of 16.12, a current ratio of 16.12 and a debt-to-equity ratio of 0.07. The business’s fifty day simple moving average is $13.93 and its 200 day simple moving average is $15.40.

Pliant Therapeutics (NASDAQ:PLRXGet Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.02). On average, analysts anticipate that Pliant Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Institutional Trading of Pliant Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in Pliant Therapeutics by 8.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 200,224 shares of the company’s stock worth $3,472,000 after buying an additional 15,578 shares during the last quarter. Barclays PLC lifted its position in Pliant Therapeutics by 165.3% in the 3rd quarter. Barclays PLC now owns 244,266 shares of the company’s stock valued at $4,236,000 after purchasing an additional 152,190 shares during the last quarter. New York State Common Retirement Fund lifted its position in Pliant Therapeutics by 3.5% in the 3rd quarter. New York State Common Retirement Fund now owns 50,575 shares of the company’s stock valued at $877,000 after purchasing an additional 1,725 shares during the last quarter. Quantbot Technologies LP boosted its stake in Pliant Therapeutics by 26.2% during the 3rd quarter. Quantbot Technologies LP now owns 32,735 shares of the company’s stock valued at $568,000 after purchasing an additional 6,802 shares during the period. Finally, Oppenheimer & Co. Inc. bought a new position in Pliant Therapeutics in the 3rd quarter worth about $210,000. 97.30% of the stock is currently owned by institutional investors and hedge funds.

About Pliant Therapeutics

(Get Free Report)

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.

Recommended Stories

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.